The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.50
Bid: 64.00
Ask: 69.00
Change: -2.50 (-3.62%)
Spread: 5.00 (7.813%)
Open: 69.00
High: 69.00
Low: 66.50
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Termination of Formal Sales Process

15 Jan 2019 11:08

RNS Number : 1482N
NetScientific PLC
15 January 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

FOR IMMEDIATE RELEASE

15 January 2019

NetScientific plc

("NetScientific" or the "Company")

Termination of Formal Sales Process

 

On 20 December 2018, NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation group, announced, inter alia, that, following its decision to conduct a review of various strategic options open to it, announced on 26 November 2018, (the "Strategic Review"), it was not in receipt of any approaches, and that it was not then in discussions with any potential offeror concerning a sale of the Company.

This remains the case and the Board is not aware of any parties who might now make such an approach or initiate such discussions.

Accordingly, the Company confirms that it has closed the formal sale process under the City Code on Takeovers and Mergers (the "Takeover Code") that it had commenced as part of the Strategic Review.

Following this announcement, the Company is no longer considered to be in an "offer period" as defined in the Takeover Code and the requirement to make disclosures under Rule 8 of the Takeover Code has now ceased.

In light of the above, the Board continues to assess all of its remaining strategic options, including seeking additional funding from its shareholders and taking material action to reduce further the Company's costs, which may include seeking a delisting.

Further announcements will be made as appropriate.

For more information, please contact:

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Jessica Cave / Chris Viggor

 

Tel: +44 (0)20 7220 1666

 

Ondra (Financial Adviser)

Michael Tory / Michiel Bröker

 

Tel: +44 (0)20 7082 8827

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

NetScientific@consilium-comms.com

Tel: +44 (0)20 3709 5700

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at http://www.NetScientific.net

Important notices

Ondra LLP, which is regulated in the United Kingdom by the Financial Conduct Authority, is acting as joint financial adviser exclusively for NetScientific and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters set out in this announcement and will not be responsible to anyone other than NetScientific for providing the protections afforded to clients of Ondra LLP, nor for providing advice in relation to any matter referred to herein.

This announcement has been prepared by, and is the sole responsibility of the Directors of NetScientific. WH Ireland Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for NetScientific and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than NetScientific for providing the protections afforded to clients of WH Ireland Limited., or for providing advice in relation to the matters referred to in this announcement.

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

Cautionary note regarding forward-looking statements

This announcement may contain certain forward-looking statements, beliefs or opinions, with respect to the financial condition, results of operations, financial performance, business strategy or plans for future operations the Company. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "hope", "aims", "continue", "will", "may", "should", "would", "could", or other words of similar meaning. These statements are based on assumptions and assessments made by the Company in light of their experience and their perception of historical trends, current conditions, future developments and other factors they believe appropriate.

By their nature, forward-looking statements involve risk and uncertainty, because they relate to events and depend on circumstances that will occur in the future and the factors described in the context of such forward-looking statements in this announcement could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this announcement.

The Company does not assume any obligation to, and does not intend to, update or correct the information contained in this announcement (whether as a result of new information, future events or otherwise), except as required by applicable law. There are several factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax rates and future business combinations or disposals.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKPDKDBKDPDD
Date   Source Headline
10th Nov 20211:58 pmRNSPDS Reports Q3 2021 Results & Business Update
4th Nov 20217:00 amRNSSofant Signs EUR7.3m ESA Contract
1st Nov 20212:16 pmRNSPDS to License Novel Proteins for Flu Vaccine
26th Oct 20217:00 amRNSEMV Capital Participates in £843k Sofant Funding
22nd Oct 202111:18 amRNSProAxsis announces the approval of a key US patent
22nd Oct 20219:04 amRNSHolding(s) in Company
21st Oct 20214:40 pmRNSSecond Price Monitoring Extn
21st Oct 20214:35 pmRNSPrice Monitoring Extension
21st Oct 20212:17 pmRNSPDS Phase 2 Clinical Trial Update
5th Oct 20217:00 amRNSPDS Phase 2 Clinical Trial Update
4th Oct 20217:00 amRNSInvestor Presentations
30th Sep 202110:22 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSGrant of Options to Directors
29th Sep 20217:00 amRNSInterim Results
20th Sep 20217:00 amRNSNotice of Results and Analyst Briefing
16th Sep 20217:00 amRNSInvestment in Martlet Capital Limited
9th Aug 20215:59 pmRNSHolding(s) in Company
30th Jul 20219:12 amRNSHolding(s) in Company
26th Jul 20214:25 pmRNSHolding(s) in Company
22nd Jul 20214:29 pmRNSHolding(s) in Company
20th Jul 20212:05 pmRNSSecond Price Monitoring Extn
20th Jul 20212:00 pmRNSPrice Monitoring Extension
16th Jul 202110:35 amRNSDirector/PDMR Shareholding
1st Jul 202112:08 pmRNSHolding(s) in Company
30th Jun 20213:42 pmRNSHolding(s) in Company
30th Jun 202110:29 amRNSHolding(s) in Company
30th Jun 202110:27 amRNSHolding(s) in Company
28th Jun 20213:18 pmRNSResult of General Meeting, TVR & PDMR Dealings
22nd Jun 20217:00 amRNSPDS Announces Closing of c. $52m Public Offering
16th Jun 20217:00 amRNSNSCI Participates in $45m PDS Equity Issue
15th Jun 20217:00 amRNSPDS announces proposed offering of common stock
10th Jun 202112:56 pmRNSResult of Placing and Total Voting Rights
10th Jun 20217:00 amRNSProposed Placing
9th Jun 20214:40 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension
8th Jun 20214:36 pmRNSPrice Monitoring Extension
8th Jun 20211:40 pmRNSPDS Announces Release of PDS0101 Interim Data
8th Jun 202111:05 amRNSSecond Price Monitoring Extn
8th Jun 202111:00 amRNSPrice Monitoring Extension
7th Jun 20214:40 pmRNSSecond Price Monitoring Extn
7th Jun 20214:35 pmRNSPrice Monitoring Extension
7th Jun 20212:06 pmRNSSecond Price Monitoring Extn
7th Jun 20212:00 pmRNSPrice Monitoring Extension
7th Jun 20217:00 amRNSProAxsis Update
3rd Jun 20214:30 pmRNSResult of AGM
3rd Jun 20218:14 amRNSHolding(s) in Company
28th May 20212:20 pmRNSHolding(s) in Company
27th May 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.